Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan

被引：0
|
作者：
Kondo, Tsunenori [1 ]
机构：
[1] Tokyo Womens Med Univ, Adachi Med Ctr, Dept Urol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2023年 / 30卷 / 09期
关键词：
D O I：
10.1111/iju.15256
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：777 / 778
页数：2
相关论文
共 50 条
  • [31] The efficacy and safety in elderly patients with advanced renal cell carcinoma: Real-world use of sorafenib in Japan.
    Tatsugami, Katsunori
    Oya, Mototsugu
    Kabu, Koki
    Akaza, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [32] Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
    Koie, Takuya
    Ohyama, Chikara
    Yoneyama, Takahiro
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Hashimoto, Yasuhiro
    Yoneyama, Tohru
    Tobisawa, Yuki
    Mori, Kazuyuki
    BMC UROLOGY, 2015, 15
  • [33] Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
    Takuya Koie
    Chikara Ohyama
    Takahiro Yoneyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Yasuhiro Hashimoto
    Tohru Yoneyama
    Yuki Tobisawa
    Kazuyuki Mori
    BMC Urology, 15
  • [34] Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma
    Geynisman, Daniel M.
    John, William S.
    Miller, Taavy A.
    Asgarisabet, Parisa
    Guttenplan, Sarah B.
    Yin, Xin
    Savill, Kristin M. Zimmerman
    Mcallister, Lindsay
    Rosenblatt, Lisa
    ONCOLOGIST, 2024,
  • [35] Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination
    Aydogdu, C.
    Paffenholz, P.
    Stelmach, R.
    Schlack, K.
    Roghmann, F.
    Handke, A.
    Mandal, S.
    Schnabel, M.
    Merseburger, A.
    Ivanyi, P.
    Tschaebitz, S.
    Darr, C.
    Gruenwald, V.
    Stief, C. G.
    Casuscelli, J.
    EUROPEAN UROLOGY, 2024, 85 : S1858 - S1858
  • [36] A COST-EFFCTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS AXITINIB VERSUS SUNITINIB FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
    Gu, J.
    VALUE IN HEALTH, 2020, 23 : S32 - S32
  • [37] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
  • [38] Real-world effectiveness and safety of first-line (1L) avelumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.
    Merseburger, Axel Stuart
    Baklanova, Olga
    Garlonta, Victor T.
    Androulakis, Nikolaos E. M.
    Christopoulou, Athina
    Timotheadou, Eleni
    Demey, Wim
    Janssen, Jan
    Ivanyi, Philipp
    Brouwers, Barbara Anna Henk
    Wynendaele, Wim
    Wang, Lusha
    Kostkova, Lenka
    Hoffman, Jason
    Manzel, Arndt
    Koumarianou, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [39] Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients
    Goto, Yusuke
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 704 - 704
  • [40] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
12345